The effect of fluoxetine and 5-HT4 serotonin receptor agonists on cerebral axonal energy metabolism and glutamate levels in multiple sclerosis.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2010-023996-25-BE

Enrollment

Registered

2010-11-25

Start date

2010-12-21

Completion date

Unknown

Last updated

2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis (both relapsing remitting and progressive forms)

Interventions

Product Name: fluoxetine Pharmaceutical Form: Coated tablet CAS Number: 54910-89-3 Other descriptive name: FLUOXETINE Concentration unit: mg milligram(s) Concentration type: up to Concentration number

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - age of 18-60 years - EDSS of =65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - ECG with QT-lengthening - Use of medication that influences the QT interval - Diabetes mellitus - pregnancy and breastfeeding - Contraindication for MRI - Use of antidepressants, MAO inhibitors, serotonin agonists

Design outcomes

Primary

Measure	Time frame
Main Objective: To study the energy metabolism of the astrocytes in multiple sclerosis. We will investigate whether elevation of cAMP signaling (by fluoxetine, cisapride and prucalopride) in astrocytes of persons with MS is able to restore axonal metabolism and reduce glutamate levels in normal appearing white matter and gray matter. ;Secondary Objective: ;Primary end point(s): - MRS: NAA and glutamaat - EDSS	—

Measure

Time frame

Main Objective: To study the energy metabolism of the astrocytes in multiple sclerosis. We will investigate whether elevation of cAMP signaling (by fluoxetine, cisapride and prucalopride) in astrocytes of persons with MS is able to restore axonal metabolism and reduce glutamate levels in normal appearing white matter and gray matter. ;Secondary Objective: ;Primary end point(s): - MRS: NAA and glutamaat - EDSS

—

Countries

Belgium

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026